6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGNPRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November, 2021.

Commission File Number: 001-40627

SOPHiA GENETICS SA

(Exact name of registrant as specified in itscharter)

Rue du Centre 172

CH-1025 Saint-Sulpice

Switzerland

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EXHIBIT INDEX

Exhibit 99.1

SOPHiA GENETICS Launches SOPHiA DDM™ forSureSelect Human All Exon v8

Newbioinformatic workflow advances analysis capabilities for whole exome assessment and interpretation

BOSTON and LAUSANNE, Switzerland, November 1,2021— SOPHiA GENETICS SA (Nasdaq: SOPH), the creator of a global data pooling and knowledge sharing platform that advances data-driven medicine, announced today they have extended their SOPHiA DDM™ Universal Whole Exome analytical capabilities to include industry leading exome SureSelect Human All Exon v8 by Agilent. The new SOPHiA GENETICS pipeline is tailored to the unique features of this product to maximize support for Agilent customers in automating their next generation sequencing (NGS) workflows with enhanced, cutting-edge interpretation tools for germline and cancer applications.

SOPHiA GENETICS’ Universal Whole Exome solution delivers a streamlined end-to-end workflow, from sample to variant report, to advance rare and inherited disease research studies using any exome product. The new SOPHiA DDM™ for SureSelect Human All Exon v8 is a fully integrated, FASTQ-to-report bioinformatic workflow for whole exome analysis and interpretation.

The SOPHiA DDM™ for SureSelect Human All Exon v8 offers:

The SOPHiA DDM™ platform supports multiple commercially available exome panels with tailored pipelines and robust analytics for each, enabling uniform coverage of the target region and a streamlined workflow to reduce overall turnaround time and accelerate rare disease characterization.

To learn more about how SOPHiA GENETICS data-driven insights are improving diagnosis, treatment, and drug development for patients and the larger medical community, visit www.sophiagenetics.com.

About SOPHiA GENETICS:

SOPHiA GENETICS is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The

SOPHiA DDM™ Platform and related solutions, products and services are currently used by more than 780 hospital, laboratory, and biopharma institutions globally.

SOPHiA GENETICS products arefor Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information included in this press releaseis about products that may or may not be available in different countries and, if applicable, may or may not have received approval ormarket clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.comto obtain the appropriate product information for your country of residence.

More info: SOPHiAGENETICS.COM; follow @SOPHiAGENETICS on Twitter.

SOPHiA GENETICS Forward-Looking Statements:

This press release contains statements thatconstitute forward-looking statements. All statements other than statements of historical facts contained in this press release, includingstatements regarding our future results of operations and financial position, business strategy, products and technology, as well as plansand objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’sbeliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties,and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, includingthose described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results willbe achieved. Such forward-looking statements contained in this document speak only as of the date of this press release. We expresslydisclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any changein our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do soby applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Media Contact:

Eliza Bamonti

ebamonti@sophiagenetics.com